NasdaqGS - Nasdaq Real Time Price USD

Adaptimmune Therapeutics plc (ADAP)

1.1300

+0.1200

(+11.88%)

At close: May 31 at 4:00 PM EDT

1.1100

-0.02

(-1.77%)

After hours: May 31 at 7:58 PM EDT

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Ga

Newsfile yesterday

GLPG

GLPGF

ADAP
+11.88%
Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCOCash runway into late 2025Conference call today at 8

Newsfile 16 days ago

ADAP
+11.88%
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). Th

Newsfile 16 days ago

ADAP
+11.88%
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) that ...

Newsfile 30 days ago

ADAP
+11.88%
Adaptimmune (ADAP) Down on End of Collaboration With Roche

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Zacks last month

ADAP
+11.88%
ROG.SW
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April 18th Investor DayPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entere

Newsfile last month

ADAP
+11.88%
Roche, Adaptimmune part ways on cell therapy research

The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

BioPharma Dive last month

ADAP
+11.88%
ROG.SW
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and transla

Newsfile 2 months ago

ADAP
+11.88%
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...

Simply Wall St. 2 months ago

ADAP
+11.88%
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Key Financial Highlights and Business Updates

GuruFocus.com 2 months ago

ADAP
+11.88%
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript March 6, 2024 Adaptimmune Therapeutics plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Adaptimmune’s Fourth Quarter and Year-End Conference Call and Business Update. I will now […]

Insider Monkey 2 months ago

ADAP
+11.88%
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams preparing for product delivery Lete-cel program transitioned back to Adaptimmune ...

Newsfile 2 months ago

ADAP
+11.88%
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023. Cintia will lead a rapidly expanding comme

Newsfile 3 months ago

ADAP
+11.88%
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EST (1:00 p.m. ...

Newsfile 3 months ago

ADAP
+11.88%
15 Top Performing European Stocks So Far in 2024

In this piece, we will take a look at the 15 top performing European stocks so far in 2024. If you want to skip our overview of the European economy and the stock climate, then you can skip ahead to 5 Top Performing European Stocks So Far in 2024. Over the course of the past […]

Insider Monkey 3 months ago

^FTSE

^GSPC

MRUS
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $1.20, representing a -1.24% change from its previous close.

Zacks 3 months ago

ADAP
+11.88%
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics ...

Newsfile 3 months ago

ADAP
+11.88%
Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, expanded its investment portfolio by adding a significant number of shares in Adaptimmune Therapeutics PLC (NASDAQ:ADAP). Baillie Gifford (Trades, Portfolio) has established itself as a prominent investment management partnership with over a century of experience.

GuruFocus.com 3 months ago

^YH103

ADAP
+11.88%
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

This month, we saw the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) up an impressive 58%. But only the myopic could...

Simply Wall St. 4 months ago

ADAP
+11.88%
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Zacks 4 months ago

ADAP
+11.88%
NVO

CTMX
-2.86%

Performance Overview

Return	ADAP	MSCI WORLD
YTD	+42.50%	+8.71%
1-Year	+10.78%	+23.02%
3-Year	-77.53%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adaptimmune Therapeutics plc (ADAP)

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Roche, Adaptimmune part ways on cell therapy research

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

15 Top Performing European Stocks So Far in 2024

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Performance Overview